Benvenue Medical has signed a group purchasing agreement for the Kiva vertebral compression fracture treatment system with Novation. The three-year contract became effective on 1 March, paving the way to offer the Kiva system through Novation.
The Kiva system was selected through the Novation Innovative Technology programme, which is designed to ensure that members have access to innovative health care technology. The process includes review by a clinical member council or task force to determine whether the technology represents incremental advantage for members. Benvenue Medical says that the Kiva system is the first clinically proven new approach to the treatment of vertebral compression fractures in over a decade.
“The decision to offer the Kiva system was based on compelling treatment effectiveness data from multiple clinical studies,” said Olya Carter, senior clinical manager at Novation.
Kiva clinical data submitted to Novation include a prospective, randomised, controlled clinical study comparing Kiva outcomes against those of balloon kyphoplasty. In addition, in multiple published studies comparing Kiva with balloon kyphoplasty, Kiva consistently improved patient outcomes in cement extravasation, cement volume and improvement in kyphotic correction. Kiva has also been shown to reduce the adjacent level fracture rate as compared to balloon kyphoplasty, as well as to significantly reduce the rate of readmissions relative to balloon kyphoplasty.
“Kiva has met the high bar set by the Novation Innovative Technology programme by providing improved patient outcomes and a reduction in the economic burden to the healthcare system, compared with balloon kyphoplasty,” said Robert Weigle, chief executive officer of Benvenue Medical. “We are pleased to offer Kiva through the Novation portfolio, which serves nearly half of all surgeries performed in the USA.”
